William Blair Forecasts Cabaletta Bio Q1 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Cabaletta Bio in a research report issued on Tuesday, April 1st. William Blair analyst S. Corwin expects that the company will earn ($0.71) per share for the quarter. The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share. William Blair also issued estimates for Cabaletta Bio's Q2 2026 earnings at ($0.74) EPS and Q3 2026 earnings at ($0.72) EPS.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.65).

A number of other analysts have also recently weighed in on the stock. Evercore ISI cut shares of Cabaletta Bio from an "outperform" rating to an "inline" rating and cut their price objective for the stock from $15.00 to $6.00 in a report on Friday, December 20th. Guggenheim reiterated a "buy" rating and set a $23.00 price target on shares of Cabaletta Bio in a research note on Tuesday, April 1st. UBS Group reduced their price target on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Morgan Stanley cut their target price on Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 1st. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 target price on shares of Cabaletta Bio in a research report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Cabaletta Bio has an average rating of "Buy" and an average target price of $21.00.

Cabaletta Bio Stock Performance

Shares of NASDAQ:CABA traded down $0.03 on Thursday, hitting $1.12. 352,304 shares of the company's stock were exchanged, compared to its average volume of 1,493,152. Cabaletta Bio has a 1-year low of $0.99 and a 1-year high of $19.04. The company has a market capitalization of $56.58 million, a PE ratio of -0.52 and a beta of 2.44. The firm's 50-day moving average is $1.95 and its 200 day moving average is $2.84.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CABA. LPL Financial LLC boosted its holdings in Cabaletta Bio by 15.6% in the 4th quarter. LPL Financial LLC now owns 42,386 shares of the company's stock valued at $96,000 after purchasing an additional 5,716 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of Cabaletta Bio by 42.2% during the 4th quarter. Intech Investment Management LLC now owns 20,203 shares of the company's stock worth $46,000 after purchasing an additional 5,999 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Cabaletta Bio during the third quarter valued at $32,000. Point72 DIFC Ltd purchased a new position in shares of Cabaletta Bio during the third quarter valued at approximately $33,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Cabaletta Bio by 6.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 125,845 shares of the company's stock worth $594,000 after purchasing an additional 7,518 shares during the last quarter.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.